OPEN COLPOSUSPENSION, TENSION-FREE VAGINAL TAPE AND TENSION-FREE OBTURATOR TAPES IN THE MANAGEMENT OF STRESS URINARY INCONTINENCE IN WOMEN- A COLOMBIAN COST-EFFECTIVENESS MODEL
Author(s)
Gamboa OA, Chicaiza L, Castillo JS, Garcia M, Sanchez J, Delgado ME, Rubio JA, Lomanto ANational University of Colombia, Bogota, Colombia
OBJECTIVES: This study aims to assess the cost-effectiveness of open colposuspension (OC) and two suburethral sling techniques: the tension free vaginal tape (tension-free vaginal tape (TVT)) and the transobturator tape (transobturator tape (TOT)) in colombian women. METHODS: As part of a clinical practice guideline development we conducted a review of literature to identify effectiveness measures for the procedures and complications for each one. To represent recurrent states of SUI, we created a Markov model. Three interventions were evaluated in four stages (continence, relapse-retreatment, incontinence and dead). Some assumptions were introduced (e.g. relapse for open colposuspension treated with vaginal tapes, TVT with TOT and TOT with TVT, two different scenarios with continent improvement). We programmed model to 85 years with a model entrance in 45 years. We used a discount rate of 3% for cost and effects (DALY: Disability-adjusted life year). All direct costs were extracted from SOAT price list. We calculated incremental cost-effectiveness ratio (ICER), generated efficiency and affordability curves. CE threshold was Gross domestic product (GDP) (3619/USD). All Colombian pesos were converted to dollars applying the following rate (2100pesos/1USD). Sensitivity analysis was done. All analysis were performed in Treeage Pro. RESULTS: In spite the most effective alternative is TVT, this is the most expensive. CE threshold for TOT was US$815 and TVT was US$948 per procedure and no more than US$2875 per each women treated. ICER for TVT and TOT comparing with OC was 9720 and 45140 US$/AVAD, without discount, exceeding GDP threshold. Discounted ICER´s were higher. CONCLUSIONS: Open colposuspension remained more CE than other alternatives. Less than US$2857 per each women treated can improve CE for TOT and TVT and reduces their ICER. Cost-effectiveness evaluation for introducing health technology and clinical practice guidelines must be developed in our country.
Conference/Value in Health Info
2009-10, ISPOR Europe 2009, Paris, France
Value in Health, Vol. 12, No. 7 (October 2009)
Code
PUK9
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Urinary/Kidney Disorders